Crossmark

Combination therapy of intravitreal ranibizumab and sub-tenon triamcinolone for treatment of resistant diabetic macular edema: a clinical study in Egypt

Crossref DOI link: https://doi.org/10.1186/s43088-025-00598-x

Published Online: 2025-01-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Khalil, Hossam Eldin M. A.

Haroun, Hazem E.

Shalan, Alaa A. I.

Mahran, Waleed M.
License Information

Text and Data Mining valid from 2025-01-23

Version of Record valid from 2025-01-23
More Information

Article History

Received: 23 July 2024

Accepted: 13 January 2025

First Online: 23 January 2025

Declarations

:

: Patients were included in this trial only after giving their written informed consent prior to any treatment for participation in this trial and for publishing of data. The Beni Suef University faculty of medicine’s ethical committee approved the study. The approval number is (FMBSUREC/05122021/Shalaan).

: The written informed consent was obtained from all study patients. All of the study participants received information about the research’s protocols as well as information about their ability to decline participation or to withdraw from the study without providing a reason. Participants received a promise of anonymity, and all information was handled in confidence. The necessary administrative requirements were met. Prior to starting the study, the research ethics committee (REC) for the faculty of medicine at Beni-Suef University was consulted.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below